The effectiveness of pharmaceutical interventions for obesity: Weight loss with orlistat and sibutramine in a United Kingdom population-based cohort

British Journal of Clinical Pharmacology

Volumn 79, Issue 6, 2015, Pages 1020-1027

  Douglas, Ian J ^a   Bhaskaran, Krishnan ^a   Batterham, Rachel L ^b,c   Smeeth, Liam ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

electronic healthcare records; obesity; orlistat; pharmacoepidemiology; sibutramine

Indexed keywords

SIBUTRAMINE; TETRAHYDROLIPSTATIN; ANOREXIGENIC AGENT; ANTIOBESITY AGENT; CYCLOBUTANE DERIVATIVE; LACTONE;

ADULT; ARTICLE; BODY MASS; CLINICAL PRACTICE; COHORT ANALYSIS; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBESITY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; UNITED KINGDOM; WEIGHT GAIN; WEIGHT REDUCTION; CASE CONTROL STUDY; DRUG EFFECTS; FACTUAL DATABASE; LONGITUDINAL STUDY; PATHOPHYSIOLOGY; PRIMARY HEALTH CARE; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME;

ADULT; ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; BODY MASS INDEX; CASE-CONTROL STUDIES; CYCLOBUTANES; DATABASES, FACTUAL; FEMALE; HUMANS; LACTONES; LINEAR MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OBESITY; PRIMARY HEALTH CARE; TIME FACTORS; TREATMENT OUTCOME; UNITED KINGDOM; WEIGHT GAIN; WEIGHT LOSS;

EID: 84930003115     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12578     Document Type: Article

References (18)

1. Department of Health. Obesity general information 2011. 2011. Available at http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/en/Publichealth/Obesity/DH-078098 (last accessed 4 October 2013).
2. WHO. Obesity and overweight. Fact sheet no. 311, updated March 2013. 2013. Available at http://www.who.int/mediacentre/factsheets/fs311/en/index.html (last accessed 5 November 2013).
3. European Medicines Agency. Questions and answers on the refusal of the marketing authorisation for Qsiva (phentermine/topiramate, EMA/109958/2013 EMEA/H/C/002350. 2013. Available at http://www.ema.europa.eu/docs/en-GB/document-library/Summary-of-opinion-Initial-authorisation/human/002350/WC500139215.pdf (last accessed 8 November 2013).
4. European Medicines Agency. Questions and answers on the withdrawal of the marketing authorisation application for Belviq (lorcaserin) EMA/309180/2013 EMEA/H/C/002597. 2013. Available at http://www.ema.europa.eu/docs/en-GB/document-library/Medicine-QA/2013/05/WC500143811.pdf (last accessed 8 November 2013).
5. National Institute for Health and Clinical Excellence. Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children. CG43, 2006. Available at http://guidance.nice.org.uk/CG43 (last accessed 4 October 2013).
6. NHLBI Obesity Education Initiative Expert Panel on the Identification, Evaluation, and Treatment of Obesity in Adults (US). Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Bethesda, MD: National Heart, Lung, and Blood Institute, 1998. Available at http://www.ncbi.nlm.nih.gov/books/NBK2003/
7. Campbell J, Dedman DJ, Eaton SC, Gallagher AM, Williams TJ,. Is the CPRD GOLD population comparable to the U.K. population? Pharmacoepidemiol Drug Saf 2013; 22: (Suppl. 1): 280. 83-6. doi: 10.1002/pds.3512.
8. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ,. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010; 69: 4-14. doi: 10.1111/j.1365-2125.2009.03537.x.
9. Bhaskaran K, Forbes H, Douglas I, Leon D, Smeeth L,. Representativeness and optimal use of body mass index (BMI) in the UK Clinical Practice Research Datalink (CPRD). BMJ Open 2013; 3: e003389. 1-8. doi: 10.1136/bmjopen-2013-003389.
10. Ara R, Blake L, Gray L, Hernández M, Crowther M, Dunkley A, Warren F, Jackson R, Rees A, Stevenson M, Abrams K, Cooper N, Davies M, Khunti K, Sutton A,. What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review. Health Technol Assess 2012; 16: iii-xiv, 1-195. doi: 10.3310/hta16050.
11. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR,. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000; 9: 160-7.
12. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, Heimburger DC, Lucas CP, Robbins DC, Chung J, Heymsfield SB,. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281: 235-42.
13. Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, Krempf M,. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group Lancet 1998; 352: 167-72.
14. Hemo B, Endevelt R, Porath A, Stampfer MJ, Shai I,. Adherence to weight loss medications; post-marketing study from HMO pharmacy data of one million individuals. Diabetes Res Clin Pract 2011; 94: 269-75. doi: 10.1016/j.diabres.2011.08.021.
15. Caterson ID, Finer N, Coutinho W, Van Gaal LF, Maggioni AP, Torp-Pedersen C, James WPT,. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab 2012; 14: 523-30. doi: 10.1111/j.1463-1326.2011.01554.x.
16. Wirth A, Krause J,. Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 2001; 286: 1331-9.
17. Smith IG, Goulder MA,. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 2001; 50: 505-12.
18. Gaciong Z, Placha G,. Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study. J Hum Hypertens 2005; 19: 737-43. doi: 10.1038/sj.jhh.1001877.